Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET/CT with ⁸⁹Zr Df-IAB22M2C in Metastatic Melanoma
NCT04955262Phase 1Withdrawn
- Sponsor
- Nektar Therapeutics
- Start
- Aug 2019
- Primary completion
- Jun 2021
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of zirconium-89 crefmirlimab berdoxam in melanoma (2 cohorts), sponsored by Nektar Therapeutics. Primary endpoints: Lesion uptake of ⁸⁹Zr-Df-IAB22M2C at 18 months and Correlation of ⁸⁹Zr Df-IAB22M2C lesion uptake with lesion size and ORR at 18 months. Planned start Aug 2019; status: withdrawn.
02
Drugs
zirconium-89 crefmirlimab berdoxam
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04955262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04955262.